TP53 and cancer: We also examined the anti-tumor effect of ACOT7 depletion in combination with Doxo (10 ng/ml) and found that combined ACOT7 Si and Doxo treatment increased anti-cancer drug sensitivity as well as accumulation of p53 and p21 via PKCζ activation in MCF7 cells (Figures 6f–h).